In the randomized controlled PARTNER ( Placement of Aortic Transcatheter Valve ) I trial , @ patients from cohort A ( operable high risk ) were randomly assigned to SAVR or TAVR ( transfemoral -LSB- TF -RSB- if iliofemoral access was suitable or transapical -LSB- TA -RSB- if not ) and received the designated treatment .